Immunogenicity and safety of a measles and rubella-containing vaccine at age 6 and 9 months in Bangladesh: an open-label, randomised trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Child & adolescent health
- Publicado em
- 31 mar 2025
- Citações
- 5
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Immunogenicity and safety of a measles and rubella-containing vaccine at age 6 and 9 months in Bangladesh: an open-label, randomised trial
Takudzwa S Sayi, Umid M Sharapov, Zachary Matson, Melissa M Coughlin, Stephen N Crooke, Qian An, Jennifer K Knapp, Asma Binte Aziz, Mohammad Yunus, Warda Haque et al.
Descritores MeSH
- Measles
- Measles Vaccine
- Rubella
- Rubella Vaccine
- Immunogenicity, Vaccine
- Immunization Schedule
- Infant
- Male
- Measles-Mumps-Rubella Vaccine
- Antibodies, Viral
Veja também
Estudos relacionados
- Evaluation of the Safety and Immunogenicity of M-M-RII (Combination Measles-mumps-rubella Vaccine): Clinical Trials of Healthy Children and Adults Published Between 2010 and 2019
- Comparative analysis of immunogenicity of Chinese MMR and MR vaccines following primary vaccination in infants in Gansu Province
- Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants
- Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study